Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Ian W. Flinn, MD PhD, David Andorsky, MD PhD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn Kolibaba, MD, Habte A. Yimer, MD, John M. Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Daniel Dingfeng Jiang, MD PhD, John C. Pesko, PhD, Tamas Vizkelety, MD, Simon Sharmokh, MPH, PharmD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137406

Published: 2020

Journal Articles

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Morton Coleman, MD FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134363

Published: 2020

Journal Articles

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

John E. Godwin, MD, Cesar O. Freytes, MD, Michael Maris, MD, Don A. Stevens, MD, Daanish Hoda, MD, Bassam Mattar, MD, Juan C. Varela, MDPhD, Mohamad Cherry, MDMS, James Essell, MD, Jay Courtright, MD, Suzanne R. Fanning, DO, Habte A. Yimer, MD, Nikolaus S. Trede, MD PhD, Marina Youssef, PharmD, James Lymp, PhD, Carlos Bachier, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-136640

Published: 2020

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, MD, David Jacob Andorsky, MD, Morton Coleman, MD FACP, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134193

Published: 2020

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Blood (2019) 134 (Supplement_1): 1887.

https://doi.org/10.1182/blood-2019-125749

Published: 2019

Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Kathryn Kolibaba, MD, John M. Burke, MD, Heather D. Brooks, MD BS, BA, Daruka Mahadevan, MD PhD, Jason Melear, MD, Charles M. Farber, MD PhD, Suzanne R. Fanning, DO, Marshall T. Schreeder, MD, Ralph V. Boccia, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3980.

https://doi.org/10.1182/blood.V126.23.3980.3980

Published: 2015

Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

Jeff P. Sharman, MD, Charles M. Farber, MD PhD, Daruka Mahadevan, MD PhD, Marshall T. Schreeder, MD, Heather D. Brooks, MD, Kathryn S. Kolibaba, MD, Suzanne R. Fanning, DO, Leonard M. Klein, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Daniel R. Greenwald, MD

Blood (2014) 124 (21): 4679.

https://doi.org/10.1182/blood.V124.21.4679.4679

Published: 2014

Journal Articles

Clinical Trial Enrolment In the Adolescent and Young Adult (AYA) Population with Hematologic Malignancies: A South Carolina (SC) Community Practice Perspective

Jill Sullivan, PhD, Jamie Jackson, Griffen Kristie, John Eberly, Jennifer Davis, Suzanne R. Fanning, DO, Hal E Crosswell, MD

Blood (2010) 116 (21): 2577.

https://doi.org/10.1182/blood.V116.21.2577.2577

Published: 2010

Journal Articles

Chemotherapy-Related Amenorrhea (CRA) among Premenopausal Patients Treated for Acute Leukemia.

Suzanne R. Fanning, DO, Tao Jin, MS, Joanne M. Hilden, MD, Anjali Advani, MD, Matt Kalaycio, MD, Alan E. Lichtin, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Halle C.F. Moore, MD

Blood (2006) 108 (11): 3315.

https://doi.org/10.1182/blood.V108.11.3315.3315

Published: 2006

NARROW

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial

Clinical Trial Enrolment In the Adolescent and Young Adult (AYA) Population with Hematologic Malignancies: A South Carolina (SC) Community Practice Perspective

Chemotherapy-Related Amenorrhea (CRA) among Premenopausal Patients Treated for Acute Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only